{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FLAG", "query": { "intervention": "FLAG" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 75, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=FLAG&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T07:12:36.824Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02412475", "title": "Epigenetic Reprogramming in Relapse AML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Acute Myeloid" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Michael Burke", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Year to 25 Years" }, "enrollment_count": 3, "start_date": "2015-02-21", "completion_date": "2017-06-21", "has_results": false, "last_update_posted_date": "2019-01-24", "last_synced_at": "2026-09-03T07:12:36.824Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Milwaukee, Wisconsin", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02412475" }, { "nct_id": "NCT02039726", "title": "(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "AML" ], "interventions": [ { "name": "Quizartinib", "type": "DRUG" }, { "name": "Salvage Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2014-05", "completion_date": "2020-09-08", "has_results": true, "last_update_posted_date": "2021-02-24", "last_synced_at": "2026-09-03T07:12:36.824Z", "location_count": 36, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 31 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02039726" }, { "nct_id": "NCT02928107", "title": "Addressing Barriers to Adult Hearing Healthcare", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hearing Loss", "Geriatric Disorder" ], "interventions": [ { "name": "Tele-HS", "type": "OTHER" }, { "name": "PCP encouragement", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "65 Years to 75 Years" }, "enrollment_count": 1146, "start_date": "2016-10-31", "completion_date": "2021-08-27", "has_results": false, "last_update_posted_date": "2021-11-09", "last_synced_at": "2026-09-03T07:12:36.824Z", "location_count": 6, "location_summary": "Ann Arbor, Michigan • New Hyde Park, New York • New York, New York + 3 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Bend", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02928107" }, { "nct_id": "NCT07264062", "title": "MetSense Pilot and Feasibility", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Serious Mental Illness", "Type 2 Diabetes" ], "interventions": [ { "name": "MetSense Risk Flag", "type": "BEHAVIORAL" }, { "name": "Usual Care", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Kaiser Permanente", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20000, "start_date": "2025-12-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-03T07:12:36.824Z", "location_count": 1, "location_summary": "Pleasanton, California", "locations": [ { "city": "Pleasanton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07264062" }, { "nct_id": "NCT03930524", "title": "Adaptive Preventive Intervention for College Alcohol Use", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "College Student Drinking" ], "interventions": [ { "name": "Personalized Normative Feedback (PNF)", "type": "BEHAVIORAL" }, { "name": "Self-Monitoring (SM)", "type": "BEHAVIORAL" }, { "name": "Web-BASICS", "type": "BEHAVIORAL" }, { "name": "Health Promotion Consultation", "type": "BEHAVIORAL" }, { "name": "M-Bridge Online Health Coach", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "18 Years to 21 Years" }, "enrollment_count": 891, "start_date": "2019-07-31", "completion_date": "2022-08-01", "has_results": true, "last_update_posted_date": "2023-04-12", "last_synced_at": "2026-09-03T07:12:36.824Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03930524" }, { "nct_id": "NCT02421939", "title": "A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia, Acute Myeloid (AML)" ], "interventions": [ { "name": "gilteritinib", "type": "DRUG" }, { "name": "LoDAC (Low Dose Cytarabine)", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "MEC (Mitoxantrone, Etoposide, Cytarabine)", "type": "DRUG" }, { "name": "FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 371, "start_date": "2015-10-20", "completion_date": "2025-02-25", "has_results": true, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-09-03T07:12:36.824Z", "location_count": 37, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 28 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02421939" }, { "nct_id": "NCT04250051", "title": "Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Acute Myeloid Leukemia", "Recurrent Myelodysplastic Syndrome", "Recurrent Myeloproliferative Neoplasm", "Refractory Acute Myeloid Leukemia", "Refractory Myelodysplastic Syndrome", "Newly Diagnosed Acute Myeloid Leukemia (AML)", "IDH1 Mutation Myeloid Neoplasms", "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Ivosidenib", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-12-21", "completion_date": "2022-12-20", "has_results": false, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-09-03T07:12:36.824Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04250051" }, { "nct_id": "NCT04584294", "title": "Patient-Centered Reproductive Decision Support Tool for Women Veterans", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Contraception", "Contraception Behavior", "Prepregnancy Health", "Reproductive Health" ], "interventions": [ { "name": "MyPath Web-Based Informational and Decision Support Tool", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "VA Office of Research and Development", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "44 Years", "sex": "FEMALE", "summary": "18 Years to 44 Years · Female only" }, "enrollment_count": 465, "start_date": "2021-03-01", "completion_date": "2025-09-30", "has_results": true, "last_update_posted_date": "2025-11-06", "last_synced_at": "2026-09-03T07:12:36.824Z", "location_count": 12, "location_summary": "San Diego, California • Aurora, Colorado • Orlando, Florida + 9 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04584294" }, { "nct_id": "NCT04240002", "title": "A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)" ], "interventions": [ { "name": "gilteritinib", "type": "DRUG" }, { "name": "fludarabine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "granulocyte colony-stimulating factor (G-CSF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "6 Months to 21 Years" }, "enrollment_count": 9, "start_date": "2020-09-04", "completion_date": "2025-03-17", "has_results": true, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-09-03T07:12:36.824Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04240002" }, { "nct_id": "NCT07228273", "title": "Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Idarubicin", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 102, "start_date": "2025-12-12", "completion_date": "2029-08-24", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-09-03T07:12:36.824Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07228273" } ] }